Literature DB >> 20717742

HIV-associated immune dysfunction and viral infection: role in the pathogenesis of AIDS-related lymphoma.

Marta Epeldegui1, Elena Vendrame, Otoniel Martínez-Maza.   

Abstract

HIV infection is associated with a much higher risk for the development of non-Hodgkin lymphoma (AIDS-NHL). The principal causes of lymphomagenesis in HIV-infected individuals are thought to be the loss of immune function seen in HIV infection, which results in the loss of immunoregulation of Epstein-Barr virus-infected B cells, as well as HIV infection-associated immune dysregulation, including chronic B-cell activation. In this review, we discuss recent reports that further support the importance of these factors, and we highlight emerging evidence of different mechanisms that potentially drive lymphomagenesis in HIV-infected individuals.

Entities:  

Mesh:

Year:  2010        PMID: 20717742      PMCID: PMC3640300          DOI: 10.1007/s12026-010-8168-8

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  94 in total

1.  Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma.

Authors:  E Zuckerman; T Zuckerman; A M Levine; D Douer; K Gutekunst; M Mizokami; D G Qian; M Velankar; B N Nathwani; T L Fong
Journal:  Ann Intern Med       Date:  1997-09-15       Impact factor: 25.391

2.  Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas.

Authors:  Jose M Polo; Przemyslaw Juszczynski; Stefano Monti; Leandro Cerchietti; Kenny Ye; John M Greally; Margaret Shipp; Ari Melnick
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-20       Impact factor: 11.205

3.  A combined computational and microarray-based approach identifies novel microRNAs encoded by human gamma-herpesviruses.

Authors:  Adam Grundhoff; Christopher S Sullivan; Don Ganem
Journal:  RNA       Date:  2006-03-15       Impact factor: 4.942

4.  EBNA1 regulates cellular gene expression by binding cellular promoters.

Authors:  Allon Canaan; Izhak Haviv; Alexander E Urban; Vincent P Schulz; Steve Hartman; Zhengdong Zhang; Dean Palejev; Albert B Deisseroth; Jill Lacy; Michael Snyder; Mark Gerstein; Sherman M Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

5.  Endogenous IL-6 and IL-10 contribute to the differentiation of CD40-activated human B lymphocytes.

Authors:  N Burdin; C Van Kooten; L Galibert; J S Abrams; J Wijdenes; J Banchereau; F Rousset
Journal:  J Immunol       Date:  1995-03-15       Impact factor: 5.422

Review 6.  Epstein-Barr virus and its role in the pathogenesis of Burkitt's lymphoma: an unresolved issue.

Authors:  Georg W Bornkamm
Journal:  Semin Cancer Biol       Date:  2009-07-18       Impact factor: 15.707

7.  Soluble CD23 potentiates interleukin-1-induced secretion of interleukin-6 and interleukin-1 receptor antagonist by human monocytes.

Authors:  A Herbelin; S Elhadad; F Ouaaz; D de Groote; B Descamps-Latscha
Journal:  Eur J Immunol       Date:  1994-08       Impact factor: 5.532

8.  Expression and Function of the Chemokine, CXCL13, and Its Receptor, CXCR5, in Aids-Associated Non-Hodgkin's Lymphoma.

Authors:  Daniel P Widney; Dorina Gui; Laura M Popoviciu; Jonathan W Said; Elizabeth C Breen; Xin Huang; Christina M R Kitchen; Juan M Alcantar; Jeffrey B Smith; Roger Detels; Otoniel Martínez-Maza
Journal:  AIDS Res Treat       Date:  2010-08-25

9.  Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones.

Authors:  D F Fiorentino; M W Bond; T R Mosmann
Journal:  J Exp Med       Date:  1989-12-01       Impact factor: 14.307

10.  Subtractive hybridization identifies novel differentially expressed ncRNA species in EBV-infected human B cells.

Authors:  Jan Mrázek; Simone B Kreutmayer; Friedrich A Grässer; Norbert Polacek; Alexander Hüttenhofer
Journal:  Nucleic Acids Res       Date:  2007-05-03       Impact factor: 16.971

View more
  40 in total

1.  Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation.

Authors:  Deborah L Regidor; Roger Detels; Elizabeth C Breen; Daniel P Widney; Lisa P Jacobson; Frank Palella; Charles R Rinaldo; Jay H Bream; Otoniel Martínez-Maza
Journal:  AIDS       Date:  2011-01-28       Impact factor: 4.177

2.  HIV and cancer in Africa: mutual collaboration between HIV and cancer programs may provide timely research and public health data.

Authors:  Sam M Mbulaiteye; Kishor Bhatia; Clement Adebamowo; Annie J Sasco
Journal:  Infect Agent Cancer       Date:  2011-10-17       Impact factor: 2.965

3.  Investigation of epstein-barr virus as a potential cause of B-cell non-Hodgkin lymphoma in a prospective cohort.

Authors:  Anneclaire J De Roos; Otoniel Martínez-Maza; Keith R Jerome; Dana K Mirick; Kenneth J Kopecky; Margaret M Madeleine; Larry Magpantay; Kerstin L Edlefsen; Andrea Z Lacroix
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-07-24       Impact factor: 4.254

4.  HMG-CoA reductase inhibitors (statins) use and risk of non-Hodgkin lymphoma in HIV-positive persons.

Authors:  Chun Chao; Lanfang Xu; Donald I Abrams; William J Towner; Michael A Horberg; Wendy A Leyden; Michael J Silverberg
Journal:  AIDS       Date:  2011-09-10       Impact factor: 4.177

5.  Polymorphisms in pattern-recognition genes in the innate immunity system and risk of non-Hodgkin lymphoma.

Authors:  Wei Hu; Bryan A Bassig; Jun Xu; Tongzhang Zheng; Yawei Zhang; Sonja I Berndt; Theodore R Holford; H Dean Hosgood; Brian Leaderer; Meredith Yeager; Idan Menashe; Peter Boyle; Kaiyong Zou; Yong Zhu; Stephen Chanock; Qing Lan; Nathaniel Rothman
Journal:  Environ Mol Mutagen       Date:  2012-10-11       Impact factor: 3.216

6.  Immune Activation: Contribution to AIDS-Associated Non-Hodgkin Lymphoma.

Authors:  Marta Epeldegui; Otoniel Martínez-Maza
Journal:  For Immunopathol Dis Therap       Date:  2015

7.  Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death.

Authors:  E T Overton; D Kitch; C A Benson; P W Hunt; J H Stein; M Smurzynski; H J Ribaudo; P Tebas
Journal:  Clin Infect Dis       Date:  2013-02-05       Impact factor: 9.079

8.  Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial).

Authors:  Marta Epeldegui; Jeannette Y Lee; Anna C Martínez; Daniel P Widney; Larry I Magpantay; Deborah Regidor; Ronald Mitsuyasu; Joseph A Sparano; Richard F Ambinder; Otoniel Martínez-Maza
Journal:  Clin Cancer Res       Date:  2015-09-17       Impact factor: 12.531

9.  HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy.

Authors:  Chad J Achenbach; Ashley L Buchanan; Stephen R Cole; Lifang Hou; Michael J Mugavero; Heidi M Crane; Richard D Moore; Richard H Haubrich; Satish Gopal; Joseph J Eron; Peter W Hunt; Benigno Rodriguez; Kenneth Mayer; Michael S Saag; Mari M Kitahata
Journal:  Clin Infect Dis       Date:  2014-02-12       Impact factor: 9.079

10.  Role of HIV-1 matrix protein p17 variants in lymphoma pathogenesis.

Authors:  Riccardo Dolcetti; Cinzia Giagulli; Wangxiao He; Marina Selleri; Francesca Caccuri; Lindsay M Eyzaguirre; Pietro Mazzuca; Silvia Corbellini; Federica Campilongo; Stefania Marsico; Emanuela Giombini; Elena Muraro; Gabriella Rozera; Paolo De Paoli; Antonino Carbone; Maria Rosaria Capobianchi; Giuseppe Ippolito; Simona Fiorentini; William A Blattner; Wuyuan Lu; Robert C Gallo; Arnaldo Caruso
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.